Most Read Articles
Dr. Wong Soon Tee, 28 May 2020
Acne is a common skin problem seen in primary care. Dr Wong Soon Tee of Assurance Skin Clinic at Mt Elizabeth Novena Hospital, Singapore shares his insights with Pearl Toh on how to manage acne in the primary care setting.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Audrey Abella, 07 Sep 2020
Mavacamten, a first-in-class myosin inhibitor, may be the first targeted therapy to address the underlying cause of obstructive hypertrophic cardiomyopathy (OHCM), the EXPLORER-HCM trial has shown.

Novel selective cathepsin K inhibitor safely reduces bone, cartilage progression in osteoarthritis

08 Jan 2020

The new selective cathepsin K inhibitor MIV-711 does not perform better than placebo in easing osteoarthritic pain, a study has shown. However, it substantially decreases bone and cartilage progression with a reassuring safety profile.

The MIV-711 showed no statistically significant changes in numerical rating scale (NRS) pain scores as compared with placebo (MIV-711 100 mg/d, –1.7; MIV-711 200 mg/d, –1.5; placebo, –1.4).

Nonetheless, its use resulted in a significant decrease in medial femoral bone area progression (p=0.002 for 100 mg/d; p=0.004 for 200 mg/d) and medial femoral cartilage thinning (p=0.023 for 100 mg/d; p=0.125 for 200 mg/d), as well as a substantial reduction in bone and cartilage biomarker levels.

Six participants experienced serious adverse events (three in the 100-mg/d group, two in the 200-mg/d group and one in the placebo group), but none of these events were treatment-related.

“This treatment may merit further evaluation as a disease-modifying osteoarthritis drug,” the authors said.

A total of 244 participants with primary knee osteoarthritis, Kellgren–Lawrence grade 2 or 3, and an nRS pain score of 4–10 were included in this 26-week randomized, double-blind, placebo-controlled phase IIa study with a 26-week open-label safety extension substudy.

Participants were randomly assigned to received MIV-700 100 (n=82) or 200 (n=81) mg daily, or matched placebo (n=77). Forty-six participants who initially received 200 mg/d and four who received placebo were given 200 mg of MIV-700 daily during the extension substudy.

The trial was limited by its relatively short duration.

“MIV-711 is a novel selective cathepsin K inhibitor with beneficial effects on bone and cartilage in preclinical osteoarthritis models,” according to the authors.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr. Wong Soon Tee, 28 May 2020
Acne is a common skin problem seen in primary care. Dr Wong Soon Tee of Assurance Skin Clinic at Mt Elizabeth Novena Hospital, Singapore shares his insights with Pearl Toh on how to manage acne in the primary care setting.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Audrey Abella, 07 Sep 2020
Mavacamten, a first-in-class myosin inhibitor, may be the first targeted therapy to address the underlying cause of obstructive hypertrophic cardiomyopathy (OHCM), the EXPLORER-HCM trial has shown.